CSPC Pharma Shares Surge Over 4% on FDA Clearance for Clinical Trial of Semaglutide Long-Acting Injection

Stock News06-10 15:54

Shares of CSPC PHARMA (01093) rose more than 4% during the trading session. At the time of writing, the stock was up 3.57% to HK$7.25, with a turnover of HK$714 million.

The increase follows an announcement from the company that its GLP-1 receptor agonist, the long-acting injection semaglutide (SYH9017), has received approval from the U.S. Food and Drug Administration (FDA) to commence clinical trials in the United States.

This product represents the company's first once-monthly long-acting formulation in the GLP-1 therapeutic area.

Recent Strategic Progress

It is noteworthy that the company has recently disclosed a series of significant developments, achieving breakthroughs across its innovative drug clinical pipeline, new drug approvals, and international strategic partnerships.

Phase III clinical data for its HER2 bispecific antibody drug combination therapy was presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. Furthermore, the drug Ennituzumab received approval for a gastric cancer indication.

Concurrently, the company has received in full the upfront payment of US$1.2 billion from AstraZeneca.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment